Kratom is not like meth. The two substances work through entirely different mechanisms in the brain, produce different effects, carry different risk profiles, and belong to different drug categories. Kratom’s active compounds primarily bind to opioid receptors, making it pharmacologically closer to opioids than to any stimulant. The comparison likely comes from the fact that kratom can produce mild stimulant-like effects at low doses, but the way it creates those effects has almost nothing in common with how methamphetamine works.
How They Work in the Brain
Methamphetamine floods the brain with dopamine, norepinephrine, and serotonin. It forces nerve cells to release large amounts of these chemicals all at once, particularly in the reward centers of the brain. This surge of dopamine is what produces the intense euphoria, energy, and focus that characterize a meth high. It also drives the drug’s powerful addiction potential.
Kratom works on a completely different system. Its two main active compounds, mitragynine and 7-hydroxymitragynine, bind to the mu-opioid receptor, the same receptor targeted by morphine and other opioids. Of the two, 7-hydroxymitragynine is the more potent, acting as a partial activator of that receptor at roughly one-tenth the binding strength of morphine. Mitragynine, the more abundant compound in the plant, has much weaker opioid activity and also interacts with adrenergic receptors, which play a role in alertness and energy. This adrenergic activity is likely what produces the mild stimulant feeling some users report at lower doses. It is not the same as methamphetamine’s mechanism of dumping dopamine into the brain’s reward circuitry.
Why Low-Dose Kratom Feels Stimulating
Kratom’s effects shift depending on how much you take. At lower doses, people commonly report increased energy, alertness, and sociability. At higher doses, the opioid effects dominate, producing sedation, pain relief, and a relaxed or euphoric feeling. This dose-dependent pattern is well documented and is one reason kratom gets loosely compared to both stimulants and opioids.
But “stimulating” does not mean “like meth.” Caffeine is a stimulant. So is a brisk walk. The energy boost from low-dose kratom is mild and comes primarily from its interaction with adrenergic receptors, not from a massive release of dopamine. Methamphetamine produces an intense, prolonged rush that can last 8 to 12 hours, driven by a mechanism that is fundamentally neurotoxic at typical recreational doses. Kratom’s stimulant properties are more comparable to a strong cup of coffee than to any amphetamine.
Long-Term Brain Damage
This is where the two substances diverge most sharply. Methamphetamine is directly neurotoxic. Chronic use causes measurable loss of dopamine transporters and serotonin transporters in the brain, along with decreased dopamine levels and structural damage to gray matter in the cortex and hippocampus. Brain imaging studies show white matter deterioration in the prefrontal region and other areas critical for decision-making and impulse control. Long-term users experience impairments in memory, attention, information processing, and executive function. There is also a documented increase in Parkinson’s disease risk among people with prolonged meth use. These are not theoretical risks; they are observable changes in the brains of people who have used the drug.
Kratom does not have a comparable body of evidence showing this kind of structural brain damage. That does not mean it is risk-free. Regular kratom use can lead to physical dependence, and stopping after extended use produces withdrawal symptoms that resemble a mild version of opioid withdrawal: runny nose, insomnia, poor concentration, muscle aches, and irritability. In documented cases, these symptoms persisted for about 10 days. That is notably less intense than withdrawal from prescription opioids or heroin, and it bears no resemblance to methamphetamine withdrawal.
Withdrawal: Two Different Experiences
Methamphetamine withdrawal is primarily psychological. The hallmark symptoms include severe depression, fatigue, intense cravings, lack of motivation, anxiety, paranoid thinking, sleep disturbances, and increased appetite. Some people experience hallucinations or hear voices. In clinical studies, 68% of people in meth withdrawal reported cravings, 56% reported exhaustion, 40% reported restlessness, and 34% reported anxiety. Elevated levels of depression, psychoticism, and hostility were measured on psychiatric scales at the start of abstinence and gradually decreased over about two weeks.
Kratom withdrawal looks more like a mild flu combined with low mood. Muscle pain, runny nose, trouble sleeping, and difficulty concentrating are the most commonly reported symptoms. There is no paranoia, no psychotic features, no hallucinations. The experience is closer to quitting a moderate opioid habit than to coming off a powerful stimulant.
Overdose Risk
Methamphetamine overdose can cause heart attack, stroke, organ failure, and dangerously high body temperature. It kills through cardiovascular collapse or hyperthermia, often rapidly.
Kratom-related deaths are rare and almost always involve other substances. A CDC analysis of 152 kratom-positive deaths between 2016 and 2017 found that fentanyl or fentanyl analogs were listed as a cause of death in 56% of cases where kratom was implicated. Heroin, benzodiazepines, and prescription opioids were also frequently present. Only seven deaths involved kratom as the sole substance detected on toxicology, and even in those cases the presence of additional undetected substances could not be ruled out. Kratom alone appears to have a relatively low overdose risk compared to both methamphetamine and traditional opioids.
Legal Classification
Methamphetamine is a Schedule II controlled substance under federal law, a category reserved for drugs with high abuse potential that can cause severe physical or psychological dependence. It sits alongside fentanyl, cocaine, and oxycodone.
Kratom is not federally scheduled in the United States. It remains legal at the federal level, though several states and municipalities have banned or restricted it. The DEA considered placing it on Schedule I in 2016 but withdrew the proposal after public backlash. This difference in legal status reflects, in part, the vastly different risk profiles of the two substances. Kratom occupies a regulatory gray area. Methamphetamine does not.
The Bottom Line on Comparisons
Calling kratom “like meth” misrepresents both substances. Kratom is pharmacologically an opioid-receptor drug with mild adrenergic properties. Methamphetamine is a powerful dopamine-releasing stimulant with well-documented neurotoxicity. They work on different brain systems, produce different subjective effects, carry different levels of risk for brain damage and overdose, and have entirely different withdrawal profiles. If kratom resembles anything in mainstream pharmacology, it is a weak opioid with a slight stimulant edge at low doses, not an amphetamine.